Skip to main content

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
Cancel
×
×
Home
  • Home
Article
  • Cited by 5
  • Cited by
    Crossref Citations
    Crossref logo
    This article has been cited by the following publications. This list is generated based on data provided by CrossRef.
    Kucwaj-Brysz, Katarzyna Kurczab, Rafał Żesławska, Ewa Lubelska, Annamaria Marć, Małgorzata Anna Latacz, Gniewomir Satała, Grzegorz Nitek, Wojciech Kieć-Kononowicz, Katarzyna and Handzlik, Jadwiga 2018. The role of aryl-topology in balancing between selective and dual 5-HT7R/5-HT1A actions of 3,5-substituted hydantoins. MedChemComm,
    Londhe, Vaishali Y. Deshmane, Aishwarya B. Singh, Sarita R. and Kulkarni, Yogesh A. 2018. Lurasidone-β-cyclodextrin complexes: Physicochemical characterization and comparison of their antidepressant, antipsychotic activities against that of self microemulsifying formulation. Journal of Molecular Structure, Vol. 1157, Issue. , p. 395.
    Goldman, Robert Loebel, Antony Cucchiaro, Josephine Deng, Ling and Findling, Robert L. 2017. Efficacy and Safety of Lurasidone in Adolescents with Schizophrenia: A 6-Week, Randomized Placebo-Controlled Study. Journal of Child and Adolescent Psychopharmacology, Vol. 27, Issue. 6, p. 516.
    Fornaro, Michele De Berardis, Domenico Perna, Giampaolo Solmi, Marco Veronese, Nicola Orsolini, Laura Buonaguro, Elisabetta Filomena Iasevoli, Felice Köhler, Cristiano André Carvalho, André Ferrer and de Bartolomeis, Andrea 2017. Lurasidone in the Treatment of Bipolar Depression: Systematic Review of Systematic Reviews. BioMed Research International, Vol. 2017, Issue. , p. 1.
    Etukala, Jagan R. Zhu, Xue Y. Eyunni, Suresh V.K. Onyameh, Edem K. Ofori, Edward Bricker, Barbara A. Kang, Hye J. Huang, Xi-Ping Roth, Bryan L. and Ablordeppey, Seth Y. 2016. Development of CNS multi-receptor ligands: Modification of known D2 pharmacophores. Bioorganic & Medicinal Chemistry, Vol. 24, Issue. 16, p. 3671.
    ×
  • Access
  • Open access

Lurasidone: a novel antipsychotic agent for the treatment of schizophrenia and bipolar depression

  • Antony Loebel (a1) and Leslie Citrome (a2)
Summary

Lurasidone is a novel antipsychotic agent approved for the treatment of schizophrenia in a number of countries including the UK, and is also approved in the USA and Canada for the treatment of major depressive episodes associated with bipolar I disorder as either a monotherapy or adjunctive therapy with lithium or valproate. In addition to full antagonist activity at dopamine D2 (K i(D2) = 1 nM) and serotonin 5-HT2A (K i(5-HT2A) = 0.5 nM) receptors, the pharmacodynamic profile of lurasidone is notable for its high affinity for serotonin 5-HT7 receptors (K i(5-HT7) = 0.5 nM) and its partial agonist activity at 5-HT1A receptors (K i(5-HT1A) = 6.4 nM). Long-term treatment of schizophrenia with lurasidone has been shown to reduce the risk of relapse. Lurasidone appears associated with minimal effects on body weight and low risk for clinically meaningful alterations in glucose, lipids or electrocardiogram parameters.

  • View HTML
      • Send article to Kindle

      To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

      Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

      Find out more about the Kindle Personal Document Service.

      Lurasidone: a novel antipsychotic agent for the treatment of schizophrenia and bipolar depression
      Available formats
      ×
      Send article to Dropbox

      To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

      Lurasidone: a novel antipsychotic agent for the treatment of schizophrenia and bipolar depression
      Available formats
      ×
      Send article to Google Drive

      To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

      Lurasidone: a novel antipsychotic agent for the treatment of schizophrenia and bipolar depression
      Available formats
      ×
Copyright
COPYRIGHT: © Royal College of Psychiatrists, 2015
This is an open-access article published by the Royal College of Psychiatrists and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Corresponding author
Correspondence to: Leslie Citrome (citrome@cnsconsultant.com)
Footnotes
Hide All

Declaration of interest

A.L. is a full-time employee of Sunovion Pharmaceuticals. In the past 12 months, L.C. was a consultant for, has received honoraria from, or has conducted clinical research supported by: Actavis (Forest Laboratories), Alexza Pharmaceuticals, Alkermes, AstraZeneca, Bristol–Myers Squibb, Eli Lilly & Company, Forum Pharmaceuticals, Genentech, Janssen Pharmaceuticals, Jazz Pharmaceuticals, Lundbeck, Medivation, Merck Worldwide, Mylan Laboratories, Novartis Pharmaceuticals, Noven Pharmaceuticals, Otsuka Pharmaceutical Group, Pfizer, Reckitt Benckiser, Reviva Pharmaceuticals, Shire, Sunovion Pharmaceuticals, Takeda Pharmaceutical Company, and Teva Pharmaceutical Industries

Footnotes
References
Hide All
1 Sunovion. Latuda (Lurasidone HCl) Tablets: Highlights of Prescribing Information. Sunovion, 2013 (http://www.latuda.com/LatudaPrescribingInformation.pdf).
2 European Medicines Agency. Latuda: EPAR – Product Information. Annex I: Summary of Product Characteristics. EMA, 2014 (http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002713/WC500164683.pdf).
3 Citrome, L. Lurasidone for schizophrenia: a review of the efficacy and safety profile for this newly approved second-generation antipsychotic. Int J Clin Pract 2011; 65: 189–210.
4 Citrome, L. Lurasidone in schizophrenia: new information about dosage and place in therapy. Adv Ther 2012; 29: 815–25.
5 Citrome, L. Lurasidone for the acute treatment of adults with schizophrenia: what is the number needed to treat, number needed to harm, and likelihood to be helped or harmed? Clin Schizophr Relat Psychoses 2012; 6: 76–85.
6 Citrome, L, Ketter, TA, Cucchiaro, J, Loebel, A. Clinical assessment of lurasidone benefit and risk in the treatment of bipolar I depression using number needed to treat, number needed to harm, and likelihood to be helped or harmed. J Affect Disord 2014; 155: 20–7.
7 Ishibashi, T, Horisawa, T, Tokuda, K, Ishiyama, T, Ogasa, M, Tagashira, R, et al. Pharmacological profile of lurasidone, a novel antipsychotic agent with potent 5-hydroxytryptamine 7 (5-HT7) and 5-HT1A receptor activity. J Pharmacol Exp Ther 2010; 334: 171–81.
8 Horiguchi, M, Huang, M, Meltzer, HY. The role of 5-hydroxytryptamine 7 receptors in the phencyclidine-induced novel object recognition deficit in rats. J Pharmacol and Exp Ther 2011; 338: 605–14.
9 Cates, LN, Roberts, AJ, Huitron-Resendiz, S, Hedlund, PB. Effects of lurasidone in behavioral models of depression. Role of the 5-HT7 receptor subtype. Neuropharmacology 2013; 70: 211–7.
10 Blier, P, Ward, NM. Is there a role for 5-HT1A agonists in the treatment of depression? Biol Psychiatry 2003; 53: 193–203.
11 Ohno, Y. Therapeutic role of 5-HT1A receptors in the treatment of schizophrenia and Parkinson's disease. CNS Neurosci Ther 2011; 17: 58–65.
12 Preskorn, S, Ereshefsky, L, Chiu, YY, Poola, N, Loebel, A. Effect of food on the pharmacokinetics of lurasidone: results of two randomized, open-label, crossover studies. Hum Psychopharmacol 2013; 28: 495–505.
13 Chiu, YY, Ereshefsky, L, Preskorn, SH, Poola, N, Loebel, A. Lurasidone drug-drug interaction studies: a comprehensive review. Drug Metabol Drug Interact 2014; 12 May [Epub ahead of print].
14 Ogasa, M, Kimura, T, Nakamura, M, Guarino, J. Lurasidone in the treatment of schizophrenia: a 6-week, placebo-controlled study. Psychopharmacology (Berl) 2013; 225: 519–30.
15 Nakamura, M, Ogasa, M, Guarino, J, Phillips, D, Severs, J, Cucchiaro, J, et al. Lurasidone in the treatment of acute schizophrenia: a double-blind, placebo-controlled trial. J Clin Psychiatry 2009; 70: 829–36.
16 Nasrallah, HA, Silva, R, Phillips, D, Cucchiaro, J, Hsu, J, Xu, J, et al. Lurasidone for the treatment of acutely psychotic patients with schizophrenia: a 6-week, randomized, placebo-controlled study. J Psychiatr Res 2013; 47: 670–7.
17 Meltzer, HY, Cucchiaro, J, Silva, R, Ogasa, M, Phillips, D, Xu, J, et al. Lurasidone in the treatment of schizophrenia: a randomized, double-blind, placebo- and olanzapine-controlled study. Am J Psychiatry 2011; 168: 957–67.
18 Loebel, A, Cucchiaro, J, Sarma, K, Xu, L, Hsu, C, Kalali, AH, et al. Efficacy and safety of lurasidone 80mg/day and 160mg/day in the treatment of schizophrenia: a randomized, double-blind, placebo- and active-controlled trial. Schizophr Res 2013; 145: 101–9.
19 Overall, JE, Gorham, DR. The Brief Psychiatric Rating Scale. Psychol Rep 1962; 10: 799–812.
20 Kay, SR, Fiszbein, A, Opler, LA. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull 1987; 13: 261–76.
21 McEvoy, JP, Citrome, L, Hernandez, D, Cucchiaro, J, Hsu, J, Pikalov, A, et al. Effectiveness of lurasidone in patients with schizophrenia or schizoaffective disorder switched from other antipsychotics: a randomized, 6-week, open-label study. J Clin Psychiatry 2013; 74: 170–9.
22 Citrome, L, Cucchiaro, J, Sarma, K, Phillips, D, Silva, R, Tsuchiya, S, et al. Long-term safety and tolerability of lurasidone in schizophrenia: a 12-month, double-blind, active-controlled study. Int Clin Psychopharmacol 2012; 27: 165–76.
23 Loebel, A, Cucchiaro, J, Xu, J, Sarma, K, Pikalov, A, Kane, JM. Effectiveness of lurasidone v. quetiapine XR for relapse prevention in schizophrenia: a 12-month, double-blind, noninferiority study. Schizophr Res 2013; 147: 95–102.
24 Harvey, PD, Siu, CO, Hsu, J, Cucchiaro, J, Maruff, P, Loebel, A. Effect of lurasidone on neurocognitive performance in patients with schizophrenia: a short-term placebo- and active-controlled study followed by a 6-month double-blind extension. Eur Neuropsychopharmacol 2013; 23: 1373–82.
25 Citrome, L, Weiden, PJ, McEvoy, JP, Correll, CU, Cucchiaro, J, Hsu, J, et al. Effectiveness of lurasidone in schizophrenia or schizoaffective patients switched from other antipsychotics: a 6-month, open-label, extension study. CNS Spectr 2013 Dec 16:1–10 [Epub ahead of print].
26 Stahl, SM, Cucchiaro, J, Simonelli, D, Hsu, J, Pikalov, A, Loebel, A. Effectiveness of lurasidone for patients with schizophrenia following 6 weeks of acute treatment with lurasidone, olanzapine, or placebo: a 6-month, open-label, extension study. J Clin Psychiatry 2013; 74: 507–15.
27 Tandon, R, Loebel, A, Phillips, D, Pikalov, A, Hernandez, O, Mao, Y, et al. A double-blind, placebo-controlled, randomized withdrawal study of lurasidone for the maintenance of efficacy in patients with schizophrenia [abstract]. Schizophr Res 2014; 153 (suppl 1): S372.
28 European Medicines Agency. Committee for Medicinal Products for Human Use (CHMP) Assessment Report: Latuda (International Non-Proprietary Name: Lurasidone). EMA (http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002713/WC500164684.pdf).
29 Judd, LL, Akiskal, HS, Schettler, PJ, Endicott, J, Maser, J, Solomon, DA, et al. The long-term natural history of the weekly symptomatic status of bipolar I disorder. Arch Gen Psychiatry 2002; 59: 530–7.
30 Ketter, TA, Citrome, L, Wang, PW, Culver, JL, Srivastava, S. Treatments for bipolar disorder: can number needed to treat/harm help inform clinical decisions? Acta Psychiatr Scand 2011; 123: 175–89.
31 Loebel, A, Cucchiaro, J, Silva, R, Kroger, H, Hsu, J, Sarma, K, et al. Lurasidone monotherapy in the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled study. Am J Psychiatry 2014; 171: 160–8.
32 Loebel, A, Cucchiaro, J, Silva, R, Kroger, H, Sarma, K, Xu, J, et al. Lurasidone as adjunctive therapy with lithium or valproate for the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled study. Am J Psychiatry 2014; 171: 169–77.
33 Montgomery, SA, Åsberg, M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979; 134: 382–9.
34 Belmaker, RH. Lurasidone and bipolar disorder. Am J Psychiatry 2014; 171: 131–3.
Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

BJPsych Bulletin
  • ISSN: 2056-4694
  • EISSN: 2056-4708
  • URL: /core/journals/bjpsych-bulletin
Please enter your name
Please enter a valid email address
Who would you like to send this to? *

CAPTCHA *

Skip to the audio challenge
×

Metrics

Altmetric attention score

Full text views

Total number of HTML views: 0
Total number of PDF views: 57 *
Loading metrics...

Abstract views

Total abstract views: 235 *
Loading metrics...

* Views captured on Cambridge Core between 2nd January 2018 - 13th June 2018. This data will be updated every 24 hours.

  • Cited by 5
  • Cited by
    Crossref Citations
    Crossref logo
    This article has been cited by the following publications. This list is generated based on data provided by CrossRef.
    Kucwaj-Brysz, Katarzyna Kurczab, Rafał Żesławska, Ewa Lubelska, Annamaria Marć, Małgorzata Anna Latacz, Gniewomir Satała, Grzegorz Nitek, Wojciech Kieć-Kononowicz, Katarzyna and Handzlik, Jadwiga 2018. The role of aryl-topology in balancing between selective and dual 5-HT7R/5-HT1A actions of 3,5-substituted hydantoins. MedChemComm,
    Londhe, Vaishali Y. Deshmane, Aishwarya B. Singh, Sarita R. and Kulkarni, Yogesh A. 2018. Lurasidone-β-cyclodextrin complexes: Physicochemical characterization and comparison of their antidepressant, antipsychotic activities against that of self microemulsifying formulation. Journal of Molecular Structure, Vol. 1157, Issue. , p. 395.
    Goldman, Robert Loebel, Antony Cucchiaro, Josephine Deng, Ling and Findling, Robert L. 2017. Efficacy and Safety of Lurasidone in Adolescents with Schizophrenia: A 6-Week, Randomized Placebo-Controlled Study. Journal of Child and Adolescent Psychopharmacology, Vol. 27, Issue. 6, p. 516.
    Fornaro, Michele De Berardis, Domenico Perna, Giampaolo Solmi, Marco Veronese, Nicola Orsolini, Laura Buonaguro, Elisabetta Filomena Iasevoli, Felice Köhler, Cristiano André Carvalho, André Ferrer and de Bartolomeis, Andrea 2017. Lurasidone in the Treatment of Bipolar Depression: Systematic Review of Systematic Reviews. BioMed Research International, Vol. 2017, Issue. , p. 1.
    Etukala, Jagan R. Zhu, Xue Y. Eyunni, Suresh V.K. Onyameh, Edem K. Ofori, Edward Bricker, Barbara A. Kang, Hye J. Huang, Xi-Ping Roth, Bryan L. and Ablordeppey, Seth Y. 2016. Development of CNS multi-receptor ligands: Modification of known D2 pharmacophores. Bioorganic & Medicinal Chemistry, Vol. 24, Issue. 16, p. 3671.
    ×
  • Access
  • Open access

Lurasidone: a novel antipsychotic agent for the treatment of schizophrenia and bipolar depression

  • Antony Loebel (a1) and Leslie Citrome (a2)
Submit a response

eLetters

No eLetters have been published for this article.

×

Reply to: Submit a response

Your details

Conflicting interests

Do you have any conflicting interests? *

Cancel
Confirm
×